Discontinuation and Switchback After Non-Medical Switching from Originator Tumor Necrosis Factor Alpha (TNF) Inhibitors to Biosimilars: A Meta-Analysis of Real-World Studies from 2012 to 2018

INTRODUCTION: To examine the prevalence rates of biosimilar discontinuation and switchback to the originator tumor necrosis factor alpha (TNF) inhibitors following non-medical switch (NMS) in patients. METHODS: Real-world studies reporting biosimilar discontinuation and switchback rates following NM...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Yifei, Skup, Martha, Yang, Min, Qi, Cynthia Z., Wu, Eric Q.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2022
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9309144/
https://www.ncbi.nlm.nih.gov/pubmed/35737227
http://dx.doi.org/10.1007/s12325-022-02173-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9309144/
https://www.ncbi.nlm.nih.gov/pubmed/35737227
http://dx.doi.org/10.1007/s12325-022-02173-7

Ejemplares similares